1. Home
  2. SCNI vs ONCO Comparison

SCNI vs ONCO Comparison

Compare SCNI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SCNI

Scinai Immunotherapeutics Ltd.

N/A

Current Price

$0.71

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

N/A

Current Price

$3.01

Market Cap

2.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCNI
ONCO
Founded
2003
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.3M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SCNI
ONCO
Price
$0.71
$3.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
44.4K
358.5K
Earning Date
05-06-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
50.00
22.80
EPS
N/A
N/A
Revenue
N/A
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.05
52 Week High
$6.18
$7.65

Technical Indicators

Market Signals
Indicator
SCNI
ONCO
Relative Strength Index (RSI) 35.48 85.68
Support Level $0.65 $2.59
Resistance Level $0.94 $3.20
Average True Range (ATR) 0.07 0.07
MACD -0.01 0.19
Stochastic Oscillator 0.53 100.00

Price Performance

Historical Comparison
SCNI
ONCO

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: